Literature DB >> 9462928

A genetic and viral load analysis of the simian immunodeficiency virus during the acute phase in macaques inoculated by the vaginal route.

D L Sodora1, F Lee, P J Dailey, P A Marx.   

Abstract

A comparative genetic analysis of SIV-infected female macaques during the first 120 days postinfection was undertaken. The same dose of a macaque-passaged SIVmac239(nef open) was administered to three macaques intravenously (i.v.) and to three macaques intravaginally (i.VAG). Clinical outcomes observed ranged from rapid to nonprogression, while two of the i.v.-infected macaques developed an uncommon hindleg paresis. Analysis of viral load (bDNA assay) determined that both i.v.- and i.VAG-infected macaques had comparable high viral loads at the observed viral peak of 14 days postinfection. A study of viral quasispecies diversity by the heteroduplex mobility assay indicated that (1) the i.v.-infected macaques had a highly heterogeneous quasispecies population similar to the infecting viral stock; and (2) in two of three i.VAG-infected macaques multiple viral genotypes (minimum, three or four) were observed in blood and lymph tissues at early times postinfection, which indicated that limited numbers of viral variants crossed the vaginal mucosa and established infection. Therefore, the route of infection can clearly influence early viral selection and diversity. In addition, a third i.VAG-infected macaque, which was a rapid progressor, did not seroconvert and progressed to AIDS in 120 days. This macaque exhibited a high viral load and heterogeneous quasispecies. These data demonstrate differences in the quasispecies complexity associated with route of infection and rate of disease progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462928     DOI: 10.1089/aid.1998.14.171

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  16 in total

1.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.

Authors:  Stephen E Braun; Ran Taube; Quan Zhu; Fay Eng Wong; Akikazu Murakami; Erick Kamau; Markryan Dwyer; Gang Qiu; Janet Daigle; Angela Carville; R Paul Johnson; Wayne A Marasco
Journal:  Hum Gene Ther       Date:  2012-09       Impact factor: 5.695

4.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Differential selection of specific human immunodeficiency virus type 1/JC499 variants after mucosal and parenteral inoculation of chimpanzees.

Authors:  Qing Wei; Patricia N Fultz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Shortening of the symptom-free period in rhesus macaques is associated with decreasing nonsynonymous variation in the env variable regions of simian immunodeficiency virus SIVsm during passage.

Authors:  P J Valli; V V Lukashov; J L Heeney; J Goudsmit
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.

Authors:  Deborah Heydenburg Fuller; Premeela A Rajakumar; Lawrence A Wilson; Anita M Trichel; James T Fuller; Tim Shipley; Mary S Wu; Kathleen Weis; Charles R Rinaldo; Joel R Haynes; Michael Murphey-Corb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.

Authors:  Ruth Dickover; Eileen Garratty; Karina Yusim; Catherine Miller; Bette Korber; Yvonne Bryson
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Authors:  Kimberly Ritola; Christopher D Pilcher; Susan A Fiscus; Noah G Hoffman; Julie A E Nelson; Kathryn M Kitrinos; Charles B Hicks; Joseph J Eron; Ronald Swanstrom
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.